Vaccine Approved

Health Canada approved in October 2017 TRUMENBA, meningococcal group B vaccine.

Pfizer Canada Inc. has announced the availability of vaccine TRUMENBA will help prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B bacteria, for individuals 10 through 25 years of age. In recent years, serogroup B invasive meningococcal disease accounted for 50 to 62% of reported cases. It is a rare but potentially devastating disease.

“Parents should never have to deal with this disease and the possibility of the death of their child, but that is unfortunately what meningitis B can do to a family,” says Kathryn Blain, Founder, Meningitis Research Foundation of Canada.

IMD is characterized by rapid onset and can be fatal in up to 10% of infected people in as little as 24 hours following the first symptoms.

“Prevention is key,” says Dr. John Yaremko, Pediatrician and Assistant Professor, McGill University.

Read the full story here

Post a comment